TABLE 3.

Primary efficacy endpoint outcomes by triptan historical experience (mITT population)

	Pooled ACHIEVE participants
	Placebo	Ubrogepant 50 mg
	(n = 912)	(n = 887)
Triptan naive
Pain freedom at 2 h, n/N (%)	61/339 (18)	78/327 (24)
Absence of MBS at 2 h, n/N (%)	105/338 (31)	132/325 (41)
Triptan responders
Pain freedom at 2 h, n/N (%)	40/350 (11)	67/331 (20)
Absence of MBS at 2 h, n/N (%)	94/349 (27)	129/332 (39)
Triptan‐insufficient responders
Pain freedom at 2 h, n/N (%)	18/223 (8)	37/228 (16)
Absence of MBS at 2 h, n/N (%)	52/223 (23)	81/226 (36)

Abbreviations: MBS, most bothersome migraine‐associated symptom; mITT, modified intent‐to‐treat.